2,246 press releases in English indexed under biotech & pharma.
Fine-tunes the Korean model Solar and deploys it on its own AI platform, AIR Studio, to automate quality-document operations Part of the MSIT•NIPA 'AX One-Stop Voucher Program'; consortium formed with Hanmi Pharmaceutical, Samsung SDS, and Selectstar SEOUL, South Korea, Sept. 9, 2026...
New York, New York--(September 10, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ: FULC).CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATIONIf you are a Fulcrum Therapeutics investor and have suffered losses, or if you have information that could assist in the Fulcrum Therapeutics investigation, you may CLICK HERE to contact us. You may also...
Robbins LLP is Investigating Allegations that Unicycive Therapeutics, Inc. Failed to Properly Inspect its Third-Party Vendor's Manufacturing Facility
TORONTO, Sept. 10, 2026 -- Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company advancing anti-inflammatory and anti-fibrotic therapies for heart disease, today announced that it has filed a preliminary short...
SOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced senior management will present during the H.C. Wainwright & Co. 28th Annual Global Investment Conference at 8:30 a.m. Eastern Time on September 16, 2026.
The biotech space is ripe with attractive rebound setups. $NVS, $NTHI, $TNON, $IRD, $LLY, $AMGN, and $BIAF
LOS ANGELES, Sept. 10, 2026 -- The Law Offices of Frank R. Cruz announces that investors with losses related to Aardvark Therapeutics, Inc. (AARD) have opportunity to lead the securities fraud class action lawsuit. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN AARDVARK...
Results from the planned interim analysis of the Phase 3 REZILIENT3 trial of zipalertinib plus chemotherapy in first-line EGFR exon 20 insertion mutation NSCLC to be presented in Presidential Symposium 2 on Sunday, September 13, 2026
César de la Fuente’s lab uses Codex and ChatGPT to search living and extinct genomes for antimicrobial candidates to fight drug-resistant infections.
Grand Opening Ceremony Scheduled for September 24, 2026 BETHLEHEM, Pa., Sept. 10, 2026 -- ABEC, a global leader in customized solutions and services for biopharmaceutical manufacturing, today announced the grand opening of its newest manufacturing facility in Wilson, North...
NEW YORK, Sept. 10, 2026 -- NYU Langone Health's Perlmutter Cancer Center has appointed Sean L. Berry, PhD, as vice chair of physics and dosimetry in the Department of Radiation Oncology. Dr. Berry brings more than 20 years of experience in radiation oncology physics, with...
Company announcement – No. 47 / 2026